アルツハイマー病治療の世界市場2027

◆英語タイトル:Global Alzheimer’s Treatment Market Outlook 2027
◆商品コード:NEST20AG01
◆発行会社(リサーチ会社):Research Nester
◆発行日:2020年6月
◆ページ数:163
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,150 ⇒換算¥435,750見積依頼/購入/質問フォーム
Site License(同一拠点閲覧用)USD5,150 ⇒換算¥540,750見積依頼/購入/質問フォーム
Enterprisewide License(同一法人閲覧用)USD7,150 ⇒換算¥750,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はResearch Nester社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Research Nester社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは、アルツハイマー病治療の世界市場について、イントロダクション、仮定、調査手法、エグゼクティブサマリー、市場動向分析、主要市場機会、市場成長、規制状況、産業リスク分析、疫学分析、特許分析、臨床試験分析、開発中の治療機器の比較分析、薬物クラス別(コリンエステラーゼ阻害剤、ドネペジル(アリセプト)、ガランタミン(ラザダイン)、N-メチル-D-アスパラギン酸(Nmda)拮抗薬)分析、流通チャネル別(オフライン、オンライン)分析、製品別(装着型デバイス、非装着型デバイス)分析、エンドユーザー別(病院、クリニック、ナーシングホーム、在宅医療)分析、地域別分析、競争構造などを総合的、多面的に調査・分析しております。
・イントロダクション
・仮定
・調査手法
・エグゼクティブサマリー
・市場動向分析
・主要市場機会
・市場成長
・規制状況
・産業リスク分析
・疫学分析
・特許分析
・臨床試験分析
・開発中の治療機器の比較分析
・アルツハイマー病治療の世界市場規模:薬物クラス別(コリンエステラーゼ阻害剤、ドネペジル(アリセプト)、ガランタミン(ラザダイン)、N-メチル-D-アスパラギン酸(Nmda)拮抗薬)
・アルツハイマー病治療の世界市場規模:流通チャネル別(オフライン、オンライン)
・アルツハイマー病治療の世界市場規模:製品別(装着型デバイス、非装着型デバイス)
・アルツハイマー病治療の世界市場規模:エンドユーザー別(病院、クリニック、ナーシングホーム、在宅医療)
・アルツハイマー病治療の世界市場規模:地域別
・競争構造
【レポートの概要】

Alzheimer’s Treatment Market Analysis – 2019-2027

According to the Alzheimer’s Association in 2020, an estimated 5.8 million people above the age of 65 in America are living with Alzheimer’s disease. This number is further predicted to increase to 13.8 million people above the age of 65 by 2050. Alzheimer’s disease is a neurological disorder which commonly occurs among the older population. The disease is characterized by the gradual degeneration of the brain tissue, which leads to temporary or permanent loss of memory. The Alzheimer’s treatment market is anticipated to grow at a CAGR of about 7.44% over the forecast period, i.e., 2020-2027. The market is further projected to attain a market value of around USD 2,008.17 million by the end of 2027.
The market for Alzheimer’s treatment is segmented by drug class, by distribution channel, by product, by end user and by region. On the basis of distribution channel, the market is segmented into online and offline segment. The offline segment is further segmented into hospital pharmacy and retail pharmacy, out of which, the offline distribution channel is anticipated to hold the leading share in the market on account of larger presence of hospital and retail pharmacies globally. On the other hand, the segment for online distribution channel is predicted to grow at the highest CAGR during the forecast period on account of rising demand for online pharmacies and various advancements in the e-commerce industry. The preference for online pharmacies is estimated to increase among the patients on account of various factors such as ease and convenience, confidentiality, low cost, and others.
Based on region, the Alzheimer’s treatment market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The market in North America is anticipated to hold the major share of Alzheimer’s treatment market on account of increasing incidences of the disease. Moreover, the presence of key players in the region is another factor predicted to lead to the growth of North America Alzheimer’s treatment market in the coming years. The market in Europe is estimated to witness significant growth and hold a vast potential for the development of the Alzheimer’s treatment market on the back of its increasing geriatric population.
Some of the key industry leaders in the global Alzheimer’s treatment market are NeuroEM Therapeutics, Inc., AbbVie Inc., Allergan Inc., H. Lundbeck A/S, Janssen, Eli Lilly and Company, Daiichi Sankyo Company Limited, Eisai Co., Ltd. and Neuronix.

【レポートの目次】

Global Alzheimer’s Treatment Market
1. Introduction
1.1. Market Definition
1.2. Market Segmentation
1.3. Product Overview
2. Assumptions And Acronyms
3. Research Methodology
3.1. Research Process
3.2. Primary Research
· Manufacturer Front
· Supplier/Distributor Front
· End User Front
3.3. Secondary Research
3.4. Market Size Estimation
4. Executive Summary- Global Alzheimer’s Treatment Market
5. Analysis Of Market Dynamics
5.1. Growth Drivers
5.2. Key Trends
6. Key Market Opportunities
7. Major Roadblocks For The Market Growth
8. Regulatory Landscape
9. Industry Risk Analysis
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. Epidemiology Analysis
11. Patent Analysis
12. Clinical Trials Analysis
13. Comparative Analysis Of Treatment Devices In Development
14. Global Alzheimer’s Treatment Market Outlook
14.1. Market Size And Forecast, 2018-2027
14.1.1. By Value (USD Million)
14.2. Global Alzheimer’s Treatment Market Segmentation, 2018-2027
14.2.1. By Treatment
14.2.1.1. By Drug Class
O Standalone Drugs, 2018-2027 (USD Million)
§ Cholinesterase Inhibitors, 2018-2027 (USD Million)
§ Donepezil (Aricept), 2018-2027 (USD Million)
§ Galantamine (Razadyne), 2018-2027 (USD Million)
§ Rivastigmine (Exelon), 2018-2027 (USD Million)
§ N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)
O Combination Drugs, 2018-2027 (USD Million)
14.2.1.2. By Distribution Channel
O Online, 2018-2027 (USD Million)
O Offline, 2018-2027 (USD Million)
§ Hospital Pharmacy, 2018-2027 (USD Million)
§ Retail Pharmacy, 2018-2027 (USD Million)
14.2.2. By Medical Device
14.2.2.1. By Product
O Wearable Device, 2018-2027 (USD Million)
O Non-Wearable Device, 2018-2027 (USD Million)
14.2.2.2. By End-User
O Hospitals, 2018-2027 (USD Million)
O Clinics, 2018-2027 (USD Million)
O Nursing Homes, 2018-2027 (USD Million)
O Home-Care Settings, 2018-2027 (USD Million)
14.2.3. By Region
14.2.3.1. North America Alzheimer’s Treatment Market, 2018-2027 (USD Million)
14.2.3.1.1. Market Overview
14.2.3.1.2. Market Size, 2018-2027 (USD Million)
14.2.3.1.3. Assessment Of Macroeconomic Factors
14.2.3.1.4. Market Segmentation
§ By Treatment
O By Drug Class
§ Standalone Drugs, 2018-2027 (USD Million)
· Cholinesterase Inhibitors, 2018-2027 (USD Million)
· Donepezil (Aricept), 2018-2027 (USD Million)
· Galantamine (Razadyne), 2018-2027 (USD Million)
· Rivastigmine (Exelon), 2018-2027 (USD Million)
· N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)
§ Combination Drugs, 2018-2027 (USD Million)
O By Distribution Channel
§ Online, 2018-2027 (USD Million)
§ Offline, 2018-2027 (USD Million)
· Hospital Pharmacy, 2018-2027 (USD Million)
· Retail Pharmacy, 2018-2027 (USD Million)
§ By Medical Device
O By Product
§ Wearable Device, 2018-2027 (USD Million)
§ Non-Wearable Device, 2018-2027 (USD Million)
O By End-User
§ Hospitals, 2018-2027 (USD Million)
§ Clinics, 2018-2027 (USD Million)
§ Nursing Homes, 2018-2027 (USD Million)
§ Home-Care Settings, 2018-2027 (USD Million)
§ By Country
O Us, 2018-2027 (USD Million)
O Canada, 2018-2027 (USD Million)
14.2.3.2. Europe Alzheimer’s Treatment Market, 2018-2027 (USD Million)
14.2.3.2.1. Market Overview
14.2.3.2.2. Market Size, 2018-2027 (USD Million)
14.2.3.2.3. Assessment Of Macroeconomic Factors
14.2.3.2.4. Market Segmentation
§ By Treatment
O By Drug Class
§ Standalone Drugs, 2018-2027 (USD Million)
· Cholinesterase Inhibitors, 2018-2027 (USD Million)
· Donepezil (Aricept), 2018-2027 (USD Million)
· Galantamine (Razadyne), 2018-2027 (USD Million)
· Rivastigmine (Exelon), 2018-2027 (USD Million)
· N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)
§ Combination Drugs, 2018-2027 (USD Million)
O By Distribution Channel
§ Online, 2018-2027 (USD Million)
§ Offline, 2018-2027 (USD Million)
· Hospital Pharmacy, 2018-2027 (USD Million)
· Retail Pharmacy, 2018-2027 (USD Million)
§ By Medical Device
O By Product
§ Wearable Device, 2018-2027 (USD Million)
§ Non-Wearable Device, 2018-2027 (USD Million)
O By End-User
§ Hospitals, 2018-2027 (USD Million)
§ Clinics, 2018-2027 (USD Million)
§ Nursing Homes, 2018-2027 (USD Million)
§ Home-Care Settings, 2018-2027 (USD Million)
§ By Country
O Uk, 2018-2027 (USD Million)
O Germany, 2018-2027 (USD Million)
O Italy, 2018-2027 (USD Million)
O France, 2018-2027 (USD Million)
O Spain, 2018-2027 (USD Million)
O Russia, 2018-2027 (USD Million)
O Rest Of Europe, 2018-2027 (USD Million)
14.2.3.3. Asia Pacific Alzheimer’s Treatment Market, 2018-2027 (USD Million)
14.2.3.3.1. Market Overview
14.2.3.3.2. Market Size, 2018-2027 (USD Million)
14.2.3.3.3. Assessment Of Macroeconomic Factors
14.2.3.3.4. Market Segmentation
§ By Treatment
O By Drug Class
§ Standalone Drugs, 2018-2027 (USD Million)
· Cholinesterase Inhibitors, 2018-2027 (USD Million)
· Donepezil (Aricept), 2018-2027 (USD Million)
· Galantamine (Razadyne), 2018-2027 (USD Million)
· Rivastigmine (Exelon), 2018-2027 (USD Million)
· N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)
§ Combination Drugs, 2018-2027 (USD Million)
O By Distribution Channel
§ Online, 2018-2027 (USD Million)
§ Offline, 2018-2027 (USD Million)
· Hospital Pharmacy, 2018-2027 (USD Million)
· Retail Pharmacy, 2018-2027 (USD Million)
§ By Medical Device
O By Product
§ Wearable Device, 2018-2027 (USD Million)
§ Non-Wearable Device, 2018-2027 (USD Million)
O By End-User
§ Hospitals, 2018-2027 (USD Million)
§ Clinics, 2018-2027 (USD Million)
§ Nursing Homes, 2018-2027 (USD Million)
§ Home-Care Settings, 2018-2027 (USD Million)
§ By Country
O China, 2018-2027 (USD Million)
O India, 2018-2027 (USD Million)
O Japan, 2018-2027 (USD Million)
O South Korea, 2018-2027 (USD Million)
O Indonesia, 2018-2027 (USD Million)
O Australia, 2018-2027 (USD Million)
O Rest Of Asia Pacific, 2018-2027 (USD Million)
14.2.3.4. Latin America Alzheimer’s Treatment Market, 2018-2027 (USD Million)
14.2.3.4.1. Market Overview
14.2.3.4.2. Market Size, 2018-2027 (USD Million)
14.2.3.4.3. Assessment Of Macroeconomic Factors
14.2.3.4.4. Market Segmentation
§ By Treatment
O By Drug Class
§ Standalone Drugs, 2018-2027 (USD Million)
· Cholinesterase Inhibitors, 2018-2027 (USD Million)
· Donepezil (Aricept), 2018-2027 (USD Million)
· Galantamine (Razadyne), 2018-2027 (USD Million)
· Rivastigmine (Exelon), 2018-2027 (USD Million)
· N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)
§ Combination Drugs, 2018-2027 (USD Million)
O By Distribution Channel
§ Online, 2018-2027 (USD Million)
§ Offline, 2018-2027 (USD Million)
· Hospital Pharmacy, 2018-2027 (USD Million)
· Retail Pharmacy, 2018-2027 (USD Million)
§ By Medical Device
O By Product
§ Wearable Device, 2018-2027 (USD Million)
§ Non-Wearable Device, 2018-2027 (USD Million)
O By End-User
§ Hospitals, 2018-2027 (USD Million)
§ Clinics, 2018-2027 (USD Million)
§ Nursing Homes, 2018-2027 (USD Million)
§ Home-Care Settings, 2018-2027 (USD Million)
§ By Country
O Brazil, 2018-2027 (USD Million)
O Mexico, 2018-2027 (USD Million)
O Rest Of Latin America, 2018-2027 (USD Million)
14.2.3.5. Middle East & Africa Alzheimer’s Treatment Market, 2018-2027 (USD Million)
14.2.3.5.1. Market Overview
14.2.3.5.2. Market Size, 2018-2027 (USD Million)
14.2.3.5.3. Assessment Of Macroeconomic Factors
14.2.3.5.4. Market Segmentation
§ By Treatment
O By Drug Class
§ Standalone Drugs, 2018-2027 (USD Million)
· Cholinesterase Inhibitors, 2018-2027 (USD Million)
· Donepezil (Aricept), 2018-2027 (USD Million)
· Galantamine (Razadyne), 2018-2027 (USD Million)
· Rivastigmine (Exelon), 2018-2027 (USD Million)
· N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)
§ Combination Drugs, 2018-2027 (USD Million)
O By Distribution Channel
O By Product
O By End-User
§ By Country
O Israel, 2018-2027 (USD Million)
O Saudi Arabia, 2018-2027 (USD Million)
O UAE, 2018-2027 (USD Million)
O South Africa, 2018-2027 (USD Million)
O Rest Of Middle East & Africa, 2018-2027 (USD Million)
15. Competitive Structure
15.1. Detailed Overview
15.2. Market Share
15.3. Assessment Of Key Product Offerings
15.4. Analysis Of Growth Strategies
15.5. Key Collaborations And Joint Ventures
15.6. Key Mergers And Acquisitions
15.7. Recent News And Developments
15.8. Key Clients And Partners
15.9. Exhaustive Analysis On Key Financial Indicators
15.10. Company Profiles Of Global Alzheimer’s Treatment Market
15.10.1. Neuroem Therapeutics, Inc.
15.10.2. Neuronix
15.10.3. Daiichi Sankyo Company Limited
15.10.4. H. Lundbeck A/S
15.10.5. Pfizer Inc.
15.10.6. Abbvie Inc
15.10.7. Eli Lilly And Company
15.10.8. Allergan, Inc.
15.10.9. Janssen Pharmaceuticals, Inc.
15.10.10. Other Market Players Strategic 16. Recommendations



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[アルツハイマー病治療の世界市場2027]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆